Biomerieux SA (BIM) fair value: what the stock is really worth
As of Nov 5, 2026: fair value (intrinsic value) of Biomerieux SA stock €74.30, price €94.75, that is 21.6% below the price, quality 69 out of 100. Rating: overvalued. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with oneYes, for free
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 1, 2026.
How to read this chart
60‑month range €66.60 – €126.56 · fair‑value band €51.06 – €92.88 · the €94.75 price screens above the €74.30 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 1, 2026.
Follow Biomerieux in your weekly email
Every Wednesday you see whether Biomerieux is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
bioMérieux S.A. develops, manufactures, and markets in vitro diagnostic solutions for infectious diseases in France, Europe, Africa, the Middle East, North and South America, the Asia Pacific, and internationally. It operates through Clinical Applications and Industrial Applications segments.
Show moreShow less
The company offers CHROMID RANGE, a chromogen culture media; air, surface, and water monitoring systems; BACT/ALERT VIRTUO, a blood sample culture system; BIOFIRE, a multiplex polymerase chain reaction system (PCR); BIOFIRE SPOTFIRE, a lowplex PCR point-of-care system; VITEK MS, a mass spectrometry system; VITEK 2, an automated identification and antimicrobial susceptibility testing (AST) system; API RANGE standardized ID strips; VITEK REVEAL, a rapid AST system; ETEST, a gradient method on culture media; BIOMERIEUX EPISEQ CS, a whole genome sequencing solution for epidemiologic monitoring; VIDAS, a specific marker of severe bacterial infections/sepsis; and Biomérieux vision suite, a software that provides information to support diagnosis and clinical decision making.
It also provides culture media and associated instruments; ARGENE that provides PCR tests for diagnosing viral respiratory diseases; EMAG system and NUCLISENS extraction reagents for DNA and RNA extraction; GENE-UP and VERIFLOW for detection of microorganisms for the food industry; ETEST for manual measurement of minimum inhibitory concentration of an antibiotic; API and RAPIDEC CARBA NP for identification of bacteria and manual antimicrobial susceptibility testing; BIOBALL for quantitative microbiological quality control; CHEMUNEX, a microbiology instrument; ENDONEXT for detection of endotoxins; TEMPO for fluorescence counting of bacteria; and Hybiome, a CLIA technology, as well as lab consultancy service and training modules.
The company was formerly known as B-D Mérieux. The company was founded in 1963 and is headquartered in Marcy-l'Étoile, France. bioMérieux S.A. operates as a subsidiary of Institut Mérieux SA.
Stock analysis
Biomerieux SA (BIM) currently trades at €94.75, while our model-based Fair Value estimate is €74.30, 22% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the DCF Models group reads highest at a median of €78.86 per share, and 4 of the 26 models we run sit above the €94.75 price.
Bear case: the Asset-Based group reads lowest at €9.07, and 22 of the 26 models stay below the price. Data coverage for this calculation is high.
Scenario range: €51.06 (bear) to €92.88 (bull), the price of €94.75 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 69/100 (solid quality), in the Healthcare sector.
Healthy Growth: Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Biomerieux SA reported revenue of €4.1B in FY2025 versus €3.4B in FY2021, a compound +4.8%/yr. Reported net income was €398M in FY2025, compounding −9.8%/yr from FY2021.
Key figures
Market cap €11.2B Large · P/E ratio 24.0 · P/S ratio 2.81 · EPS (TTM) €3.94 · Dividend yield 1.0% · Net margin 11.6% · Return on equity 11.2% · Return on assets (EBIT) 11.2%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 55 out of 100 (low confidence).
What moves the price
The share trades about 16% below its 52-week high and 42% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −8% fair-value upside, at −22%, BIM screens richer than that median.
Fair Value models
Bear€51.06Fair Value €74.30Bull€92.88
Price €94.75 · Downside -21.6%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then (€2.51 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.75/100
Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Revenue growth 1 year
+2.3%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+4.3%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+5.5%
Start year 2020 (pandemic). Over 10 years: +7.6% a year
Revenue growth 20 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+7.3%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate.
+0.6%
Earnings growth per share plus dividend.
Earnings per share, growth per year−0.4%
Dividend (yield on the price)1.0%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.−0.4% vs 11.3%, slowing
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.18% → 14%
Pace: the 5-year rate starts in 2020 (pandemic)
Growth Forecast
A lot of optimism in the price
The price assumes more growth than the company has delivered so far and more than analysts expect.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+10.2%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
+4.1%
Yearly sales growth analysts expect, extended to five years.
After inflation (euro area: IMF forecast 2.2% a year to 2030, 2.6% from 2016 to 2025) that is about +7.9% a year for the price and +1.8% for the forecasts.
News mood ⓘNews mood, the average tone of recent news (34 articles), rated against how stocks are usually covered. 🚀 Hype = unusually upbeat · 🙂 Positive = above average · 😐 Neutral = typical · 🙁 Negative = below average · 😨 Very negative = unusually downbeat. It reflects the tone of coverage, not our valuation.Positive
Recent news coverage is more positive than average.
AI conclusion: The main strength is the new SPINCHIP point-of-care platform rollout in Europe after the SpinChip acquisition, while the main weak point remains inconclusive evidence of a durable moat amid only moderate margins and returns.
Main risk: Ongoing infringement actions by Labrador Diagnostics against VIDAS 3 and by Qiagen over tuberculosis detection patents could force product modifications, recalls or licensing costs that hit sales of established immunoassay and molecular lines.
Bull case: BioMérieux could integrate its AI partnerships such as with Mila to enhance test accuracy and speed, differentiating SPINCHIP and VIDAS from low-cost rivals and expanding into new emergency and antimicrobial-resistance applications.
Bear case: If cheaper Asian rivals and patent disputes intensify, bioMérieux could lose significant share in high-growth POC segments and face restricted sales of core platforms, limiting overall revenue growth from its GO•28 plan.
bioMérieux recently launched SPINCHIP, a compact point-of-care platform that measures high-sensitivity cardiac troponin I from one drop of blood in roughly ten minutes. The rollout starts in Europe and supports the GO•28 plan following the acquisition of SpinChip. Our models see the stock as overvalued. Will this accelerate adoption in emergency settings enough to lift overall growth, or will it mainly cannibalize existing lab-based testing?
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Diagnostics & Research · 126 stocks
Beats the industry median on 11/15 measures
Overall it ranks above its industry peers.
Valuation
Quality Score69 · Top 25%
Fair Value upside−21.6% · Above median
Profitability
Return on equity (12 months)11.2% · Above median
Return on assets7.1% · Top 25%
Net margin (12 months)11.6% · Above median
Operating margin (12 months)15.2% · Above median
Growth and dividend
Revenue growth (quarter YoY)−3.9% · Bottom 25%
Dividend yield (12 months)1.0% · Below median
Balance sheet
Debt / equity0.05× · Below median
Valuation Multiplesvs Diagnostics & Research median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Biomerieux SA Fair Value". https://www.fairvalue-calculator.com/stock/BIM
Frequently asked questions
Is Biomerieux SA (BIM) overvalued or undervalued?
As of Nov 1, 2026, our model estimates a fair value of €74.30 versus a price of €94.75, about 22% lower (overvalued).
What is the fair value of BIM?
Our model-based fair value for Biomerieux SA is €74.30 (as of Nov 1, 2026), built from audited fundamentals. The current price: €94.75.
What is the quality score of BIM?
Biomerieux SA has a Quality Score of 69/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Biomerieux SA (BIM)?
Our model-based price target is the fair value of €74.30 (as of Nov 1, 2026) from 26 valuation models. Cautious scenario €51.06, optimistic scenario €92.88. It is a calculation from audited fundamentals, not an analyst target.
What is the Biomerieux SA stock forecast for 2026?
Our models put fair value at €74.30, about 22% lower versus a price of €94.75 (overvalued). Cautious scenario €51.06, optimistic scenario €92.88. The calculation is refreshed regularly with new filings.
What is the revenue of Biomerieux SA (BIM)?
Biomerieux SA reported trailing-twelve-month revenue of about €4.0B (latest available figure, as of Nov 1, 2026).
Does Biomerieux SA pay a dividend?
Biomerieux SA currently shows a dividend yield of 1.03% relative to its recent price (as of Nov 1, 2026).
What growth is priced into Biomerieux SA (BIM)?
For today's price to be fair in a discounted-cash-flow model, Biomerieux SA would have to grow free cash flow by +10.2 % per year for five years (discount rate 8.7 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +5.5 % per year. As of Nov 1, 2026.
What discount rate (WACC) does the fair value of BIM use?
Our models discount Biomerieux SA at 8.7 %: a base by market capitalisation (large), damped by beta 0.55, country premium for France. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Biomerieux SA that is +10.2 % per year a year over ten years, using the same discount rate (8.7 %) and the same formula as our fair value.
How much growth has Biomerieux SA (BIM) delivered so far?
Over the past 5 years revenue at Biomerieux SA grew +5.5 % a year. The price currently implies +10.2 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Biomerieux SA (BIM) growing?
The median revenue growth in the sector is +6.2 % a year. That is the yardstick for the growth priced into Biomerieux SA (+10.2 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Biomerieux SA (BIM)?
The free-cash-flow yield on the price is 4.04 %: that much free cash flow Biomerieux SA produces per unit of market value. When it exceeds the discount rate of our models (8.7 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Biomerieux SA (BIM)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Biomerieux SA it is €74.30 per share (as of Nov 1, 2026), against a price of €94.75. It is the blended result of 26 valuation models (cash flow, earnings, asset, dividend).
Is Biomerieux SA stock overvalued or undervalued in 2026?
As of Nov 1, 2026, BIM trades above its calculated fair value: price €94.75, fair value €74.30, a gap of about −22% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of BIM?
No. The price is what the market pays today (€94.75); the fair value is what the company's own numbers justify (€74.30). For Biomerieux SA the two are €20.45 per share apart. That gap is exactly why we show both numbers side by side.
How much is Biomerieux SA worth?
The market values Biomerieux SA at about €11.2B (market capitalisation, as of Nov 1, 2026). Per share that is €94.75; our models calculate a fair value of €74.30 per share.
What do the bullish and bearish scenarios say about BIM?
Our models span a range for Biomerieux SA: cautious scenario €51.06, base €74.30, optimistic €92.88 per share (as of Nov 1, 2026, price €94.75). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of BIM?
Biomerieux SA trades at a price-to-earnings ratio of 24.0 (as of Nov 1, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of €74.30 is built from several models across several years. Median P/E at fiscal year-end, 9 fiscal years (2017 to 2025), reported earnings: 33.0. Other multiples: PEG 1.7, P/B 2.7, P/S 2.8, EV/EBITDA 10.3.
What is the PEG ratio of BIM?
The PEG ratio of Biomerieux SA is 1.69 (P/E divided by earnings growth, as of Nov 1, 2026). That is above 1, so the growth is already paid for in the price.
How solid is the balance sheet of Biomerieux SA (BIM)?
Balance-sheet figures for Biomerieux SA (as of Nov 1, 2026): return on equity 11.2%, debt of 0.05 per unit of equity. They feed the Quality Score of 69/100, which measures business quality independently of the share price.
How far is BIM from its 52-week high?
Biomerieux SA trades at €94.75, about 16% below its 52-week high of €113.25 and 42% above the low of €66.60 (as of Nov 5, 2026). Distance from the high says nothing about value: that is what the fair value of €74.30 is for.
Which stocks are comparable to Biomerieux SA?
From the same area (Healthcare) we also value Thermo Fisher Scientific Inc, Danaher Corporation, WuXi AppTec Co, Lonza Group, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Biomerieux SA stock attractive at the current price?
The data as of Nov 1, 2026: price €94.75, calculated fair value €74.30 (−22%), Quality Score 69/100, from 26 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of BIM calculated?
We run Biomerieux SA through 26 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of €74.30, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 15.5% above its aggregate fair value. Biomerieux SA itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Biomerieux SA (BIM)?
The closing price on Nov 5, 2026 was €94.75. Our model-based fair value is €74.30, about 22% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Biomerieux SA right now?
The price sits above even our optimistic bull case (€92.88). The favourable scenario is already priced in. Solid but not exceptional quality (69/100) and above fair value, neither a clear bargain nor a standout compounder. A fairly wide model range (€51.06 to €92.88) leaves room in how you read the outcome.
Where does the earnings growth of Biomerieux SA (BIM) come from?
Earnings per share at Biomerieux SA grew +12.1 % a year from 2014 to 2025. Broken into its drivers: revenue per share +8.2 %, EBIT margin +0.0 %, tax rate +1.0 %, residual (interest, one-offs) +2.6 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.
Key figures of Biomerieux SA
How large is the market capitalisation of Biomerieux SA (BIM)?
The market capitalisation of Biomerieux SA is €11.2B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Biomerieux SA (BIM)?
The price-to-sales ratio of Biomerieux SA is 2.81 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Biomerieux SA (BIM)?
Earnings per share at Biomerieux SA are €3.94 (price ÷ EPS = P/E 24.0). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Biomerieux SA (BIM)?
The dividend yield of Biomerieux SA is 1.0% (payout 24.9%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Biomerieux SA (BIM)?
The net margin of Biomerieux SA is 11.6% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Biomerieux SA (BIM)?
The return on equity (ROE) of Biomerieux SA is 11.2% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Biomerieux SA (BIM)?
On an EBIT basis the return on assets of Biomerieux SA is 11.2% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Biomerieux SA (BIM)?
The operating margin of Biomerieux SA is 15.2% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Biomerieux SA (BIM)?
Revenue at Biomerieux SA is growing −3.9% versus a year earlier (3y avg +4.3%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Biomerieux SA (BIM)?
Earnings per share at Biomerieux SA are growing +41.9% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net cash does Biomerieux SA (BIM) hold?
Biomerieux SA holds more cash than debt, €108M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch Biomerieux SA in the live analysis
One click puts Biomerieux SA on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Broad data
Nov 1, 2026